Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Intercalated methotrexate shows more adverse effects in DLBCL treatment than end-use

Key clinical point: Intercalated high-dose methotrexate (HD-MTX) was associated with increased toxicity and R-CHOP delays compared to end of treatment (EOT) delivery.

Major finding: Intercalating HD-MTX was the only factor independently associated with R-CHOP delay (HR 2.84 ; P = .001).

Study details: Retrospective analysis of DLCBL patients who received CNS prophylaxis with either i-HD-MTX (n=204) or EOT HD-MTX (n=130).

Disclosures: The abstract contained no conflict information.


Wilson M et al. European Hematology Association virtual annual meeting. 2020; Abstract S236.